Phenex in $135m deal with Janssen for IL-17 blockers
This article was originally published in Scrip
Executive Summary
Phenex Pharmaceuticals has entered into an agreement with Janssen Biotech and its affiliates to jointly discover compounds that target the nuclear hormone receptor RORγT, with a view to developing treatments for chronic autoimmune and inflammatory disorders including rheumatoid arthritis, psoriasis and inflammatory bowel disease.